These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 19137770)

  • 21. Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management.
    Ong CK; Tan WC; Chan LC; Abdul Razak M
    Med J Malaysia; 2012 Apr; 67(2):222-3. PubMed ID: 22822651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidermal growth factor receptor inhibitor-related folliculitis.
    Tangri N; Al Hammadi A; Gerstein W
    Dermatitis; 2007 Sep; 18(3):178-9. PubMed ID: 17725926
    [No Abstract]   [Full Text] [Related]  

  • 23. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
    Requena C; Llombart B; Sanmartín O
    Cutis; 2012 Aug; 90(2):77-80. PubMed ID: 22988651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acneiform reaction to erlotinib.
    Schalock PC; Zug KA
    Dermatitis; 2007 Dec; 18(4):230-1. PubMed ID: 18021605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Acneiform eruption from epidermal growth factor receptor inhibitors].
    Martínez de Lagrán Z; Ratón JA; Lasa O; Acebo E; Díaz-Pérez JL
    Actas Dermosifiliogr; 2005 Sep; 96(7):450-4. PubMed ID: 16476273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma.
    Diamantis ML; Chon SY
    J Drugs Dermatol; 2010 Feb; 9(2):169-71. PubMed ID: 20214183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients.
    de Noronha e Menezes NM; Lima R; Moreira A; Varela P; Barroso A; Baptista A; Parente B
    Eur J Dermatol; 2009; 19(3):248-51. PubMed ID: 19258241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor.
    Van Doorn R; Kirtschig G; Scheffer E; Stoof TJ; Giaccone G
    Br J Dermatol; 2002 Sep; 147(3):598-601. PubMed ID: 12207609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor.
    Fernandez-Galar M; España A; López-Picazo JM
    Clin Exp Dermatol; 2004 Mar; 29(2):138-40. PubMed ID: 14987267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erlotinib induced target-like purpura.
    Rungtrakulchai R; Rerknimitr P
    Dermatol Online J; 2014 Feb; 20(2):. PubMed ID: 24612572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Dermal toxicity of erlotinib].
    Bourra H; Hassam B
    Pan Afr Med J; 2013; 15():47. PubMed ID: 24106575
    [No Abstract]   [Full Text] [Related]  

  • 32. A comedonal acneiform eruption following dovitinib therapy.
    Gracia-Cazaña T; Pastushenko I; Concellón MA; Grasa-Jordán MP
    Clin Exp Dermatol; 2014 Oct; 39(7):842-3. PubMed ID: 25196373
    [No Abstract]   [Full Text] [Related]  

  • 33. [Functional impairment and radiologic fasciitis under erlotinib therapy].
    Osdoit S; Wierzbicka E; Guillet G
    Ann Dermatol Venereol; 2011; 138(6-7):494-8. PubMed ID: 21700070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.
    Jacot W; Bessis D; Jorda E; Ychou M; Fabbro M; Pujol JL; Guillot B
    Br J Dermatol; 2004 Jul; 151(1):238-41. PubMed ID: 15270903
    [No Abstract]   [Full Text] [Related]  

  • 35. [Adverse cutaneous reactions to erlotinib].
    Pitarch G; Garde J; Torrijos A; Juárez A; Febrer MI; Camps C
    Actas Dermosifiliogr; 2008; 99(1):54-60. PubMed ID: 18206087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An acneiform eruption due to erlotinib: prognostic implications and management.
    Journagan S; Obadiah J
    J Am Acad Dermatol; 2006 Feb; 54(2):358-60. PubMed ID: 16443077
    [No Abstract]   [Full Text] [Related]  

  • 37. Two cases of acneiform eruption induced by inhibitor of epidermal growth factor receptor.
    Gencoglan G; Ceylan C
    Skin Pharmacol Physiol; 2007; 20(5):260-2. PubMed ID: 17641540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
    Guttman-Yassky E; Mita A; De Jonge M; Matthews L; McCarthy S; Iwata KK; Verweij J; Rowinsky EK; Krueger JG
    Eur J Cancer; 2010 Jul; 46(11):2010-9. PubMed ID: 20621734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Higher severity grade of erlotinib-induced rash is associated with lower skin phototype.
    Luu M; Boone SL; Patel J; Sullivan P; Rademaker AW; Balagula Y; Lacouture ME
    Clin Exp Dermatol; 2011 Oct; 36(7):733-8. PubMed ID: 21689147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cutaneous side effects of EGF receptor inhibitors].
    Nassar D; Soutou B; Aractingi S
    Bull Cancer; 2009 Dec; 96 Suppl():S85-91. PubMed ID: 20034874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.